on September 3, 2002
Published online before print September 3, 2002, doi: 10.1161/01.HYP.0000034740.99323.8A
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 27, 2002
From the Department of Clinical and Experimental Medicine, School of Medicine, Federico II University Hospital (G.deS.), Naples; Department of Cardiovascular Disease, University of Perugia and Hospital R. Silvestrini (P.V.), Perugia; Cardiology, Hospital San Pietro Vernotico (S.P.); and ANMCO Study Center (M.G., A.P.M.), Florence, Italy. * To whom correspondence should be addressed. E-mail: simogi{at}unina.it.
Abstract—To evaluate the prognostic impact of left ventricular (LV) mass exceeding individual needs to compensate hemodynamic load, the percentage of excess of echocardiographic LV mass in relation to individual ideal value predicted by gender, stroke work, and height (in meter2.7) from a reference population was assessed in 1019 white hypertensives (627 women [24% obese] and 392 men [17% obese, P<0.02 versus women]) without prevalent cardiovascular disease or type 1 diabetes, from the Italian multicenter, prospective study MAVI. Low LV mass (<73% of predicted) was found in 36 patients (3.5%), 661 had appropriate LV mass, and 322 (37%) had inappropriate LV mass. During follow-up (35±11 months), 52 fatal or nonfatal primary cardiovascular events occurred. Age, systolic blood pressure, and LV mass as a percentage of the predicted value were significant predictors of cardiovascular events (all P<0.01), independently of gender, glycemia, antihypertensive treatments, and body mass index, even in subgroups with or without LV hypertrophy. Survival analysis showed that cardiovascular risk increased stepwise from the lowest to the highest quintile of LV mass as a percentage of predicted value (P<0.01). The excess LV mass showed incremental prognostic value compared with assessment of traditional LV mass (P<0.01). Thus, inappropriate LV mass predicts a risk of cardiovascular events, independently of risk factors, and remains a significant predictor of risk either in the presence or in the absence of traditionally defined LV hypertrophy.
Revised on July 17, 2002
Prognosis of Inappropriate Left Ventricular Mass in Hypertension. The MAVI Study
Giovanni de Simone*;
Key words: hypertrophy • arterial pressure • cardiovascular diseases • echocardiography • myocardium
This article has been cited by other articles:
 |
|
 |
|
  G. Mancia, R. Sega, M. Bombelli, F. Quarti-Trevano, R. Facchetti, and G. Grassi Should White-Coat Hypertension in Diabetes Be Treated? Pro Diabetes Care, November 1, 2009; 32(suppl_2): S305 - S309. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Pavlopoulos and P. Nihoyannopoulos Pulse pressure/stroke volume: a surrogate index of arterial stiffness and the relation to segmental relaxation and longitudinal systolic deformation in hypertensive disease Eur J Echocardiogr, June 1, 2009; 10(4): 519 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Verma, A. Meris, H. Skali, J. K. Ghali, J. M. O. Arnold, M. Bourgoun, E. J. Velazquez, J. J.V. McMurray, L. Kober, M. A. Pfeffer, et al. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. J. Am. Coll. Cardiol. Img., September 1, 2008; 1(5): 582 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Muiesan, M. Salvetti, A. Paini, C. Agabiti-Rosei, C. Monteduro, G. Galbassini, E. Belotti, C. Aggiusti, D. Rizzoni, M. Castellano, et al. Inappropriate Left Ventricular Mass in Patients With Primary Aldosteronism Hypertension, September 1, 2008; 52(3): 529 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. de Simone, J. S. Gottdiener, M. Chinali, and M. S. Maurer Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study Eur. Heart J., March 2, 2008; 29(6): 741 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Agabiti-Rosei, M. L. Muiesan, and M. Salvetti Review: New approaches to the assessment of left ventricular hypertrophy Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 119 - 128. [Abstract] [PDF]
|
|
|
|
|
|
B. Lopez, J. M. Castellano, A. Gonzalez, J. Barba, and J. Diez Association of Increased Plasma Cardiotrophin-1 With Inappropriate Left Ventricular Mass in Essential Hypertension Hypertension, November 1, 2007; 50(5): 977 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Llamas, S. Belanger, S. Picard, and C. F. Deschepper Cardiac mass and cardiomyocyte size are governed by different genetic loci on either autosomes or chromosome Y in recombinant inbred mice Physiol Genomics, October 19, 2007; 31(2): 176 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Muiesan, M. Salvetti, A. Paini, C. Monteduro, G. Galbassini, B. Bonzi, P. Poisa, E. Belotti, C. Agabiti Rosei, D. Rizzoni, et al. Inappropriate Left Ventricular Mass Changes During Treatment Adversely Affects Cardiovascular Prognosis in Hypertensive Patients Hypertension, May 1, 2007; 49(5): 1077 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Kane, A. Behfar, R. B. Dyer, D. F. O'Cochlain, X.-K. Liu, D. M. Hodgson, S. Reyes, T. Miki, S. Seino, and A. Terzic KCNJ11 gene knockout of the Kir6.2 KATP channel causes maladaptive remodeling and heart failure in hypertension Hum. Mol. Genet., August 1, 2006; 15(15): 2285 - 2297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chinali, G. de Simone, M. J. Roman, E. T. Lee, L. G. Best, B. V. Howard, and R. B. Devereux Impact of Obesity on Cardiac Geometry and Function in a Population of Adolescents: The Strong Heart Study J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2267 - 2273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Souzeau, B. Llamas, S. Belanger, S. Picard, and C. F. Deschepper A Genetic Locus Accentuates the Effect of Volume Overload on Adverse Left Ventricular Remodeling in Male and Female Rats Hypertension, January 1, 2006; 47(1): 128 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F. Deschepper, J. L. Olson, M. Otis, and N. Gallo-Payet Characterization of blood pressure and morphological traits in cardiovascular-related organs in 13 different inbred mouse strains J Appl Physiol, July 1, 2004; 97(1): 369 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Schneider, A. U. Klingbeil, C. Delles, M. Ludwig, R. E. Kolloch, M. Krekler, K. O. Stumpe, and R. E. Schmieder Effect of Irbesartan Versus Atenolol on Left Ventricular Mass and Voltage: Results of the CardioVascular Irbesartan Project Hypertension, July 1, 2004; 44(1): 61 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. de Simone Concentric or Eccentric Hypertrophy: How Clinically Relevant Is the Difference? Hypertension, April 1, 2004; 43(4): 714 - 715. [Full Text] [PDF]
|
|
|
|
 |
|
 M.D. Witham, J.I. Davies, A. Dawson, P.G. Davey, and A.D. Struthers Hypothetical economic analysis of screening for left ventricular hypertrophy in high-risk normotensive populations QJM, February 1, 2004; 97(2): 87 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Alehagen, G. Lindstedt, H. Eriksson, and U. Dahlstrom Utility of the Amino-Terminal Fragment of Pro-Brain Natriuretic Peptide in Plasma for the Evaluation of Cardiac Dysfunction in Elderly Patients in Primary Health Care Clin. Chem., August 1, 2003; 49(8): 1337 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kozakova, G. de Simone, C. Morizzo, and C. Palombo Coronary Vasodilator Capacity and Hypertension-Induced Increase in Left Ventricular Mass Hypertension, February 1, 2003; 41(2): 224 - 229. [Abstract] [Full Text] [PDF]
|
|